Hutchison China Meditech Limited Total Voting Rights (6918F)
31 October 2018 - 6:00PM
UK Regulatory
TIDMHCM
RNS Number : 6918F
Hutchison China Meditech Limited
31 October 2018
Total Voting Rights
London: Wednesday, October 31, 2018: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market
that as at October 31, 2018, the issued share capital of Chi-Med
consisted of 66,618,660 ordinary shares of US$1.00 each, with each
share carrying one right to vote and with no shares held in
treasury.
The above figure of 66,618,660 may be used by shareholders as
the denominator for the calculations by which they could determine
if they are required to notify their interest in, or a change to
their interest in, Chi-Med under the Financial Conduct Authority's
Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 66,618,660 ordinary shares
would be equivalent to 66,618,660 CREST depositary interests (each
equating to one ordinary share) which are traded on AIM or, if the
CREST depositary interests were converted in their entirety,
equivalent to 133,237,320 American depositary shares (each equating
to one-half of one ordinary share) which are traded on Nasdaq.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President,
Corporate Finance & Development +852 2121 8200
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
Mainland China - Sam Shen, Edelman +86 1367 179 1029 (Mobile)
sam.shen@edelman.com
Nominated Advisor
Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREANEEDASPFEF
(END) Dow Jones Newswires
October 31, 2018 03:00 ET (07:00 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024